| Literature DB >> 24962034 |
Zara Shubber1, Sharmistha Mishra2, Juan F Vesga3, Marie-Claude Boily3.
Abstract
INTRODUCTION: The HIV Modes of Transmission (MOT) model estimates the annual fraction of new HIV infections (FNI) acquired by different risk groups. It was designed to guide country-specific HIV prevention policies. To determine if the MOT produced context-specific recommendations, we analyzed MOT results by region and epidemic type, and explored the factors (e.g. data used to estimate parameter inputs, adherence to guidelines) influencing the differences.Entities:
Keywords: HIV; HIV infection; HIV prevention policy; Modes of Transmission model; epidemic appraisal; key populations
Mesh:
Year: 2014 PMID: 24962034 PMCID: PMC4069382 DOI: 10.7448/IAS.17.1.18928
Source DB: PubMed Journal: J Int AIDS Soc ISSN: 1758-2652 Impact factor: 5.396
Methods for the assessment of the quality of MOT studies
| Recommendations for conducting a high quality MOT | Assessment of quality |
|---|---|
| Recommendation 1: Synthesize and triangulate available data | We extracted information on the search strategy used by the authors to parameterize the MOT:
The authors reported that a systematic review was conducted The search strategy was described in detail and appeared systematic but was not reported as being systematic The authors used multiple sources to locate data to parameterize the MOT The search strategy used was not reported |
| Recommendation 2: Emphasize the use of the MOT model as a process, that is, where there is insufficient data, use the MOT as a process to help identify gaps in knowledge | We extracted information on:
The number of studies that described the MOT exercise as a “process” The key knowledge and data gaps reported by the authors The recommendations made for enhanced surveillance or for further research studies to be conducted in order to address these gaps in knowledge |
| Recommendation 3: Improve the consideration given to data quality | We extracted information on the main data limitations encountered by the authors. |
| Recommendation 4: Adopt a bottom-up approach, that is, an approach that ensures that sufficient data is available to parameterize the model before making changes to tailor the MOT to more finely represent the local setting (e.g. by adding additional sub-groups not included in the simple MOT). A “bottom-up” approach involves only tailoring the MOT if there is a need to do so and enough data to parameterize it. | We extracted information on the number of studies that:
Amended the MOT by adding sub-groups specific to the local context Used a basic model (did not add sub-groups) Considered tailoring the MOT but judged that it was not possible due to data limitations. Those studies that considered tailoring the model due to a perceived need but instead used a basic model due to data limitations were considered as adopting a “bottom-up approach.” |
| Recommendation 5: Validate the model results | We extracted information on the number of studies that compared the MOT results with other epidemiological evidence. We included information on what was validated, against what data and the findings. |
| Recommendation 6: Establish minimum conditions for conducting the MOT analysis | The minimum conditions are not specified in the guidelines. The new EPI-MOT tool [ |
| Recommendation 7: Strengthen the uncertainty analysis e.g. extend the uncertainty analysis by allowing for correlated errors, or examining the influence of modelling assumptions on heterogeneities in risk within groups. Present the uncertainty estimates graphically. | We extracted information on:
The number of studies that conducted a sensitivity or uncertainty analysis The nature of any sensitivity or uncertainty analyses conducted If the uncertainty was presented graphically |
| Recommendation 8: Be clear about what the model results mean, that is, the MOT estimates the short-term distribution of infections and does not necessarily reflect the epidemic drivers | We extracted information on whether the authors interpreted the MOT estimated annual fraction of new HIV infections as:
The distribution of new infections The source of new infections The driver of the epidemic |
Figure 1Results of systematic search for eligible studies.
Summary of included MOT studies
| Assumed HIV prevalence (%) | Risk groups with largest FNI (estimate, minimum-maximum) | Priority group | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Country | Year | LRH | FSW | CLIENT | MSM | PWID | Type | 1 | 2 | FNI | NP | MOT |
| Latin America and Caribbean | ||||||||||||
| Iran [ | 2010 | 0.04 | 5 | 0.5 | 2.8 | 15 | C | PWID (56, 48–62)% | Part. PWID (12, 10–15)% | HRG | HRG | HRG; GP |
| Morocco [ | 2010 | 0.08 | 2 | 0.5 | 2 | 2 | LL | LRH (26, 18–38)% | Client (24, 13–32)% | GP | HRG | HRG |
| West Africa | ||||||||||||
| Benin [ | 2009 | 1 | 25.5 | 4.5 | 10 | 6 | G | LRH (30, 25–35)% | Part. client (15, 13–18)% | GP | HRG; GP | HRG; GP |
| Burkina Faso [ | 2009 | 2 | 21 | 4 | 22 | 6 | G | LRH (49, 42–59)% | Part. CHS (11, 8–13)% | GP | HRG; GP | HRG; GP |
| Cote D’Ivoire [ | 2009 | 4.5 | 18.3 | 13.4 | 18.5 | 5.6 | G | CHS (32, 25–40)% | LRH (23, 17–29)% | GP | HRG; GP | HRG; GP |
| Ghana [ | 2008 | 1.9 | 37.5 | 12.3 | 25.3 | 5.6 | G | LRH (30, 22–36)% | Part. client (22, 19–25)% | GP | HRG; GP | HRG; GP |
| Nigeria [ | 2009 | 3.6 | 34 | 10.8 | 13.5 | 5.6 | G | LRH (42, 30–45)% | Part. CHS (15, 12–18)% | GP | HRG; GP | HRG; GP |
| Senegal [ | 2009 | 0.5 | 19.5 | 2 | 22 | 2 | C | Part. CHS (35, 25–45)% | CHS (22, 10–32)% | GP | HRG | HRG; GP |
| Sierra Leone [ | 2010 | 1.2 | 8.5 | 1.5 | 7.5 | 4 | G | Clients (26%, nc) | LRH (16%, nc) | HRG | HRG; GP | HRG; GP |
| East and Southern Africa | ||||||||||||
| Kenya [ | 2005 | 7.5 | 40 | 8.1 | 20 | 20 | G | LRH (30%, nc) | Part. CHS (28%, nc) | GP | HRG; GP | HRG; GP |
| Kenya [ | 2006 | 7.4 | NS | NS | NS | NS | G | Part. CHS (28%, nc) | CHS (20%, nc) | GP | HRG; GP | HRG; GP |
| Lesotho [ | 2008 | 23.2 | NS | NS | NS | NA | G | LRH (35, 35–62)% | CHS (31, 16–31)% | GP | HRG; GP | GP |
| Malawi [ | 2008 | 13 | 70.7 | 17 | 20 | NA | G | LRH (37%, nc) | Part. CHS (27%, nc) | GP | HRG; GP | GP |
| Swaziland [ | 2008 | 33 | 60 | 45 | 40 | 25.9 | G | LRH (50, 48–65)% | Part. CHS (21, 12–21)% | GP | HRG; GP | GP |
| Uganda [ | 2008 | 5 | 47.2 | 8.5 | 43 | 30 | G | LRH (43, 41–46)% | CHS (24, 21–27)% | GP | HRG; GP | HRG; GP |
| Zambia [ | 2008 | 14.3 | 68.7 | 39 | 33 | NA | G | Part. CHS (37%, nc) | CHS (34%, nc) | GP | HRG; GP | HRG; GP |
| Zimbabwe [ | 2010 | 14.3 | 54.3 | 19.3 | 16.8 | 12.4 | G | LRH (55, 50–68)% | Part. CHS (14%, nc) | GP | HRG; GP | HRG; GP |
| Eastern Europe and Russia | ||||||||||||
| Moldova [ | 2010 | 0.1 | 6.8 | 1.3 | 0.7 | 17.8 | C | Part. PWID (31, 18–51)% | Part. CHS (16, 5–28)% | GP | HRG | HRG; GP |
| Russia [ | 2002 | NS | NS | NS | NS | NS | C | PWID (61%, nc) | Part. HRG (25%, nc) | HRG | HRG | HRG |
| ASIA | ||||||||||||
| Cambodia [ | 2002 | NS | NS | NS | NS | NS | G | Part. HRG (56%, nc) | FSW & clients (24%, nc) | GP | HRG; GP | HRG; GP |
| India [ | 2010 | 0.3 | 4.9 | 1 | 7.3 | 9.2 | C | LRH (63%, nc) | PWID (14%, nc) | GP | HRG | NA |
| Indonesia [ | 2002 | NS | NS | NS | NS | NS | C | PWID (82%, nc) | FSW & clients (9.5%, nc) | HRG | HRG | HRG |
| Philippines [ | 2010 | 0 | 0.2 | 0.01 | 1 | 0.06 | LL | MSM (89%, nc) | OPW (7%, nc) | HRG | HRG | HRG |
| Thailand [ | 2005 | 0.6 | 5 | 5 | 7 | 45 | C | LRH (43%, nc) | MSM (21%, nc) | GP | HRG | HRG; GP |
| Latin America and Caribbean | ||||||||||||
| Dominican Republic [ | 2010 | 0.8 | 4.8 | 2.2 | 6.1 | 12.8 | C | MSM (33, 23–45)% | LRH (32, 23–38)% | HRG | HRG | HRG |
| El Salvador [ | 2011 | 0.3 | 4.1 | 2 | 9.8 | 3 | C | MSM (36, 27–44)% | Client (15, 8–30)% | HRG | HRG | HRG |
| Honduras [ | 2002 | NS | NS | NS | NS | NS | G | MSM (40%, nc) | Part. HRG (36%, nc) | HRG | HRG; GP | HRG |
| Jamaica [ | 2012 | 1.1 | 4.4 | 3.5 | 15 | NA | G | MSM (32, 25–40)% | CHS (22, 15–30)% | HRG | HRG; GP | HRG; GP |
| Nicaragua [ | 2011 | 0.6 | 1.9 | 1 | 7.5 | 1.9 | C | MSM (44, 25–52)% | CHS (21, 16–38)% | HRG | HRG | HRG |
| Peru [ | 2010 | 0.3 | 0.9 | 0.8 | 5.2 | 13 | C | MSM (55, 35–66)% | LRH (16, 5–22)% | HRG | HRG | HRG |
Year of MOT estimate;
Epidemic type (LL=low-level, C=concentrated, G=generalized);
Where sensitivity or uncertainty analysis is conducted, the minimum and maximum estimates are provided. Where such analyses were not conducted only the estimate is provided (nc=not conducted);
Priority risk groups for prevention resources (FNI=group based on largest fraction of new HIV infection, NP=group based on numerical proxy method, MOT=actual recommendations made by each MOT study author);
No group specifically specified by the country MOT authors but authors recommended that resources should be based on MOT outputs – here assumed based on the top group±second group if estimated FNI is within 10% of the top risk group and/or overlapping confidence intervals. For example, if the authors did not explicitly say that MSM should be prioritized but instead said that resources should be aligned with the MOT results and MSM acquired the largest FNI, MSM here are considered to have been prioritized; CHS=casual heterosexual sex; FSW=female-sex worker; HRG=high-risk groups; GP=general population (includes bridging populations); LRH=low-risk heterosexual adult; MSM=men who have sex with other men; NA=not applicable (e.g. no specific groups prioritized, group excluded or risk groups not disaggregated); NS=not specified; OPW=overseas Philippino worker; Part=partner; PWID=people who inject drugs; SA=sensitivity analysis.
Figure 2The FNI among high-risk groups by region.
Figure 3The FNI among high-risk groups by the assumed HIV prevalence in the low-risk group.
Figure 4The FNI among MSM versus their population size.
Figure 5The FNI among the low-risk group versus their population size.
Quality of the conducted MOT studies
| Country | Search; R1 | Process; R2 | Reported data gaps | Recommend research based on data gaps; R2/3 | Other groups considered; R4 | Model; R4 | Validation; R5 | EPI-MOT; R6 | UA or SA | Interpretation |
|---|---|---|---|---|---|---|---|---|---|---|
| Middle East and North Africa | ||||||||||
| Iran [ | SR | No | Yes | Yes | Yes | BM | Yes | No | Yes | Distribution |
| Morocco [ | SR | Yes | Yes | Yes | Yes | BM | Yes | No | Yes | Distribution, driver |
| West Africa | ||||||||||
| Benin [ | MS | No | Yes | Yes | No | BM | Yes | No | Yes | Distribution |
| Burkina Faso [ | MS | No | Yes | Yes | No | BM | Yes | No | Yes | Distribution |
| Cote D’Ivoire [ | MS | No | Yes | Yes | No | BM | Yes | No | Yes | Distribution |
| Ghana [ | MS | No | Yes | Yes | No | BM | Yes | No | Yes | Distribution |
| Nigeria [ | MS | Yes | Yes | Yes | Yes | BM | Yes | No | Yes | Distribution |
| Senegal [ | MS | No | Yes | Yes | No | BM | Yes | No | Yes | Distribution |
| Sierra Leone [ | MS | Yes | Yes | Yes | Yes | CM (AG) | Yes | No | No | Distribution, driver |
| East and Southern Africa | ||||||||||
| Kenya [ | NS | No | No | Yes | No | BM | Yes | No | No | Distribution |
| Kenya [ | MS | No | Yes | Yes | Yes | CM (AG) | No | No | No | Distribution |
| Lesotho [ | MS | Yes | Yes | Yes | Yes | BM (EG) | Yes | No | Yes | Distribution, driver |
| Malawi [ | NS | No | No | No | Yes | BM (EG) | Yes | No | Yes | Distribution |
| Swaziland [ | MS | Yes | Yes | Yes | Yes | BM | Yes | No | Yes | Distribution, driver |
| Uganda [ | MS | Yes | Yes | Yes | Yes | BM | Yes | No | Yes | Distribution |
| Zambia [ | MS | Yes | Yes | No | Yes | BM (EG) | Yes | No | No | Distribution |
| Zimbabwe [ | MS | Yes | Yes | No | Yes | BM | Unclear | No | Yes | Distribution, driver |
| Eastern Europe and Russia | ||||||||||
| Moldova [ | SR | No | Yes | Yes | Yes | BM | Yes | No | Yes | Distribution |
| Russia [ | NS | No | No | No | No | BM | No | No | No | Distribution |
| Asia | ||||||||||
| Cambodia [ | NS | No | No | No | No | BM | No | No | No | Distribution |
| India [ | MS | No | No | No | No | BM | Yes | No | Yes | Distribution |
| Indonesia [ | NS | No | No | No | No | BM | No | No | No | Distribution |
| Philippines [ | MS | No | Yes | Yes | Yes | CM (AG, EG) | Yes | No | No | Distribution |
| Thailand [ | NS | No | No | Yes | No | BM | Yes | No | No | Distribution |
| Latin America and Caribbean | ||||||||||
| Dominican Republic [ | MS | Yes | Yes | Yes | Yes | CM (AG) | No | No | Yes | Distribution |
| El Salvador [ | MS | Yes | Yes | Yes | Yes | BM | No | No | Yes | Distribution |
| Honduras [ | NS | No | No | No | No | BM | No | No | No | Distribution |
| Jamaica [ | MS | Yes | Yes | Yes | Yes | BM (EG) | Yes | No | Yes | Distribution, driver |
| Nicaragua [ | MS | Yes | Yes | Yes | Yes | CM (AG) | No | Yes | Yes | Distribution |
| Peru [ | MS | Yes | Yes | Yes | No | BM | No | No | Yes | Distribution |
Further details on the data limitations encountered by studies are provided in Supplementary file;
Further details on the methods used for these analyses and their results can be found in Supplementary file;
Interpretations of MOT annual fraction of new HIV infections (FNI) (Distribution=the annual fraction of new infections, Source=the source of new infections, Driver=the drivers of the epidemic);
passed Part1 EPI-MOT [12] when tool retrospectively applied;
Lesotho, Sierra Leone, Swaziland, Uganda and Zimbabwe included any contextual, social or structural factors that increase the risk of HIV transmission into their definition of “driver,” Jamaica defined “driver” using a “R0 analysis” and Morocco defined high-risk groups as the “drivers” and not the low-risk population who had the largest FNI;
Uncertainty analyses conducted later as part of the West Africa multi-country report; AG=additional risk groups added; BM=basic model; CM=customized model; EG=excluded risk groups that were deemed not important in the local context. This was not defined as a customisation but rather the application of the basic model with the population size of the relevant group set to zero; MS=multiple sources; R1–R8=recommendations 1 to 8 based on Case et al. guidelines [7]; SA=sensitivity analysis; SR=systematic review; UA=uncertainty analysis.